Simeon George Discloses Investment at ADARx Pharmaceuticals with 9.3% Stake

Simeon George, through SR One Capital Management, disclosed a 9.3% stake in ADARx Pharmaceuticals (ADRX) post-IPO. The investment includes converted preferred shares and IPO purchases, with a 180-day lock-up period. SR One plans long-term growth and holds registration rights post-lock-up. ADRX completed its IPO on Sept. 28, 2026.

Original reporting

tradingview.com

Published Oct 5, 2026, 9:36 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 5, 2026, 9:48 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Simeon George Discloses Investment at ADARx Pharmaceuticals with 9.3% Stake — source image — Source · tradingview.com

Decision brief

The 30-second read

$ADRXNeutralLow

Why it matters

The stake adds credibility and may attract further institutional interest, but the 180‑day lock‑up tempers short‑term trading activity.

Market read

A new large shareholder in a freshly listed biotech could influence price dynamics, though immediate impact is muted by lock‑up provisions.

What to watch

Potential future dilution if additional shares are issued or if SR One later sells after lock‑up.

Relevance 6/10Novelty 5/10Timing: after‑hours filing on Oct 5, 2026

Background

ADARx Pharmaceuticals completed its IPO on Sept 28, 2026. The 13D filing reveals a strategic post‑IPO investment by a biotech‑focused fund.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ADRXNeutralHigh confidence

Context

Schedule 13D filing shows SR One Capital Management taking a 9.3% stake in ADARx post‑IPO, introducing lock‑up and registration rights that may affect near‑term liquidity.

Expected impact

modest upside as market prices in the backing, limited by lock‑up constraints

Evidence & confidence

First public disclosure of a significant post‑IPO investor with lock‑up; no immediate sell pressure, but share availability is restricted.

Market effects

Sector

May boost sentiment in the biotech IPO space as a reputable investor backs ADARx.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Low global relevance beyond niche biotech investors.

Counterpoint

What could challenge this read

The lock‑up could suppress price gains and signal limited immediate demand.

Key entities

Individual
Simeon George
Managing member of SR One Capital Management, leading the investment.
Firm
SR One Capital Management
Biotech‑focused investment firm taking a 9.3% stake in ADARx.

Read at source ← All news

$ADRXHighAI 8/10

ADARx Advances Agazisiran, Onvuzosiran Programs; Key Clinical Readouts Set For 2027

ADARx Pharmaceuticals (ADRX) reported Q3 2026 revenue of $2.2M, up from $1.6M in 2025, with R&D and G&A expenses rising. Net loss widened to $28.1M. The company has $901M in cash and expects funds to last until 2030. ADARx advanced clinical trials for agazisiran and onvuzosiran, with key data expected in 2027. The company completed an IPO raising $513.2M and a private placement with AbbVie for $89.3M.

rttnews.comNov 13

$ADRXMed

ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates

ADARx Pharmaceuticals, Inc. (ADRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates – Completed initial public offering (IPO) and concurrent private placement generating aggregate gross proceeds of approximately $602.5 million; cash position expected to fund operations

SEC EDGAR 8-KNov 12

$ADRXMed

Morgan Stanley initiates ADARx stock with overweight rating

Morgan Stanley initiated coverage on ADARx Pharmaceuticals (NASDAQ:ADRX) with an overweight rating and a $32.00 price target, suggesting 81% upside. The company has a market cap of $1.98 billion and a pipeline of liver-targeted treatments. UBS and TD Cowen also initiated coverage with Buy ratings and higher price targets. ADARx recently completed an IPO, raising $446.3 million.

investing.comOct 20

$ADRXHighAI 9/10

ADARx raises $513.2M as underwriters exercise IPO option

ADARx Pharmaceuticals (NASDAQ:ADRX) raised $513.2M after underwriters exercised their option to buy 3.9M additional shares at $17.00 each in its IPO. Total shares sold reached 30.2M. AbbVie bought 5.3M shares in a private placement at the same price, adding $89.3M. Combined proceeds totaled $602.5M. J.P. Morgan, Morgan Stanley, and others managed the offering.

investing.comOct 1

$ADRXHighAI 8/10

ADARx Pharmaceuticals, Inc. (ADRX) Greenshoe Fully Exercised; IPO Gross Now ~$513.2M

ADARx Pharmaceuticals' underwriters fully exercised the greenshoe option, adding 3.94M shares to the IPO at $17 each. The total IPO size is now 30.19M shares, raising ~$513.2M. Including a concurrent private placement, total gross proceeds reached ~$602.5M, according to the company.

tradingview.comOct 1

$ADRXMedAI 9/10

ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering

ADARx Pharmaceuticals (ADRX) announced the closing of an additional 3.94 million shares sold in its IPO, raising $513.2 million at $17 per share. Including a concurrent private placement, total gross proceeds reached $602.5 million. J.P. Morgan, Morgan Stanley, and others acted as underwriters.

globenewswire.comOct 1